Whats new
Whats new.
Canaccord Genuity - Not LAG-ing Behind in the Immune Oncology Race; Initiating Coverage with a BUY Rating and A$1 tgt (Analyst: Elyse Shapiro)
April 29th 2024
For a copy of this research report please contact your Canaccord Genuity advisor